One Year Alemtuzumab - What have we Learned in Clinical Practice? Exchange of Experience between Experts on Treatment of Multiple Sclerosis

被引:3
作者
Bayas, A. [1 ]
Baum, K. [2 ]
Bitsch, A. [3 ]
Haas, J. [4 ]
Hellwig, K. [5 ]
Lang, M. [6 ]
Lee, D. -H. [7 ]
Rosenkranz, T. [8 ]
Schreiber, M.
Ulzheimer, J. C. [9 ]
Ziemssen, T. [10 ]
机构
[1] Klinikum Augsburg, Neurol Klin & Klin Neurophysiol, Stenglinstr 2, D-86156 Augsburg, Germany
[2] Oberhavel Kliniken GmbH, Abt Neurol, Klin Hennigsdorf, Hennigsdorf, Germany
[3] Ruppiner Kliniken GmbH, Neurol Klin, Neuruppin, Germany
[4] Jud Krankenhaus Berlin, Zentrum Multiple Sklerose, Berlin, Germany
[5] Ruhr Univ Bochum, St Josef Hosp, Neurol, Bochum, Germany
[6] Nervenfacharztliche Gemeinschaftspraxis Ulm, Ulm, Germany
[7] Neurol Univ Klin, Erlangen, Germany
[8] Asklepios Klin St Georg, Abt Neurol, Hamburg, Germany
[9] Caritas Krankenhaus Bad Mergentheim, Neurol Klin, Bad Mergentheim, Germany
[10] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Neurol Klin & Poliklin, Dresden, Germany
关键词
multiple sclerosis; alemtuzumab; pharmacovigilance; infusion management;
D O I
10.1055/s-0035-1555891
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The approval of alemtuzumab in European countries in 2013 has broadened the therapeutic armamentarium for relapsing-remitting multiple sclerosis (RRMS). Meanwhile, first experiences with the new treatment are available. The question, however, arises as to who the appropriate patient is. What has to be considered regarding infusion management? Which adverse effects have to be expected in clinical practice and how will the necessary treatment controls be assured? Clinicians and neurologists in private practice shared their experience with alemtuzumab at a workshop in Frankfurt in January 2015. The expert group has developed the following recommendations regarding alemtuzumab in clinical practice.
引用
收藏
页码:535 / 541
页数:7
相关论文
共 8 条
  • [1] Bayas A, 2015, 67 ANN M AM AC NEUR
  • [2] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
    Cohen, Jeffrey A.
    Coles, Alasdair J.
    Arnold, Douglas L.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Fisher, Elizabeth
    Brinar, Vesna V.
    Giovannoni, Gavin
    Stojanovic, Miroslav
    Ertik, Bella I.
    Lake, Stephen L.
    Margolin, David H.
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1819 - 1828
  • [3] Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
    Coles, A. J.
    Fox, E.
    Vladic, A.
    Gazda, S. K.
    Brinar, V.
    Selmaj, K. W.
    Skoromets, A.
    Stolyarov, I.
    Bass, A.
    Sullivan, H.
    Margolin, D. H.
    Lake, S. L.
    Moran, S.
    Palmer, J.
    Smith, M. S.
    Compston, D. A. S.
    [J]. NEUROLOGY, 2012, 78 (14) : 1069 - 1078
  • [4] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
    Coles, Alasdair J.
    Twyman, Cary L.
    Arnold, Douglas L.
    Cohen, Jeffrey A.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Miller, Tamara
    Fisher, Elizabeth
    Sandbrink, Rupert
    Lake, Stephen L.
    Margolin, David H.
    Oyuela, Pedro
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1829 - 1839
  • [5] Engelmann U, 2015, 67 ANN M AM AC NEUR
  • [6] Gold R, 2014, DIAGNOSE THERAPIE MU
  • [7] Evidence for a two-stage disability progression in multiple sclerosis
    Leray, Emmanuelle
    Yaouanq, Jacqueline
    Le Page, Emmanuelle
    Coustans, Marc
    Laplaud, David
    Oger, Joel
    Edan, Gilles
    [J]. BRAIN, 2010, 133 : 1900 - 1913
  • [8] Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
    Tuohy, Orla
    Costelloe, Lisa
    Hill-Cawthorne, Grant
    Bjornson, Ingunn
    Harding, Katharine
    Robertson, Neil
    May, Karen
    Button, Tom
    Azzopardi, Laura
    Kousin-Ezewu, Onajite
    Fahey, Michael T.
    Jones, Joanne
    Compston, D. Alastair S.
    Coles, Alasdair
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (02) : 208 - 215